CONMED CORPORATION (CNMD) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 455.40M USD | Liabilities, Current |
| Cash and equivalents | (m) | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 239.77M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 360.18M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $455.40M | (m) | (m) | $239.77M | $360.18M | (m) |
| 2025-12-31 | (m) | $315.04M | (m) | (m) | $247.83M | $355.54M | (m) |
| 2025-09-30 | (m) | $314.70M | (m) | (m) | $224.94M | $364.36M | (m) |
| 2025-06-30 | (m) | $294.84M | (m) | (m) | $234.15M | $362.25M | (m) |
| 2025-03-31 | (m) | $283.15M | (m) | (m) | $221.14M | $354.68M | (m) |
| 2024-12-31 | (m) | $278.13M | (m) | (m) | $237.73M | $346.72M | (m) |
| 2024-09-30 | (m) | $282.31M | (m) | (m) | $231.23M | $342.55M | (m) |
| 2024-06-30 | (m) | $266.41M | (m) | (m) | $239.22M | $322.36M | (m) |
| 2024-03-31 | (m) | $291.40M | (m) | (m) | $241.46M | $322.30M | (m) |
| 2023-12-31 | (m) | $310.73M | (m) | (m) | $242.28M | $318.32M | (m) |
| 2023-09-30 | (m) | $376.32M | (m) | (m) | $230.20M | $325.82M | (m) |
| 2023-06-30 | (m) | $353.17M | (m) | (m) | $229.26M | $327.31M | (m) |
| 2023-03-31 | (m) | $320.69M | (m) | (m) | $213.18M | $335.37M | (m) |
| 2022-12-31 | (m) | $296.55M | (m) | (m) | $191.34M | $332.32M | (m) |
| 2022-09-30 | (m) | $208.58M | (m) | (m) | $197.29M | $304.81M | (m) |
| 2022-06-30 | (m) | $201.09M | (m) | (m) | $202.12M | $289.71M | (m) |
| 2022-03-31 | (m) | $187.60M | (m) | (m) | $183.25M | $253.73M | (m) |
| 2021-12-31 | (m) | $196.65M | (m) | (m) | $183.88M | $231.64M | (m) |
| 2021-09-30 | (m) | $183.19M | (m) | (m) | $165.43M | $228.57M | (m) |
| 2021-06-30 | (m) | $198.46M | (m) | (m) | $168.97M | $211.32M | (m) |
| 2021-03-31 | (m) | $182.16M | (m) | (m) | $163.95M | $205.80M | (m) |
| 2020-12-31 | (m) | $190.20M | (m) | (m) | $177.15M | $194.87M | (m) |
| 2020-09-30 | (m) | $179.04M | (m) | (m) | $166.59M | $182.67M | (m) |
| 2020-06-30 | (m) | $150.61M | (m) | (m) | $143.41M | $175.72M | (m) |
| 2020-03-31 | (m) | $160.00M | (m) | (m) | $166.50M | $174.54M | (m) |
| 2019-12-31 | (m) | $188.09M | $25.86M | (m) | $189.10M | $164.62M | (m) |
| 2019-09-30 | (m) | $160.66M | $30.07M | (m) | $173.28M | $173.92M | (m) |
| 2019-06-30 | (m) | $155.80M | $22.55M | (m) | $179.04M | $172.80M | (m) |
| 2019-03-31 | (m) | $151.27M | $23.41M | (m) | $172.19M | $171.09M | (m) |
| 2018-12-31 | (m) | $160.94M | $17.51M | (m) | $181.55M | $154.60M | (m) |
| 2018-09-30 | (m) | $164.89M | $29.69M | (m) | $161.00M | $153.62M | (m) |
| 2018-06-30 | (m) | $176.67M | $23.40M | (m) | $161.69M | $143.41M | (m) |
| 2018-03-31 | (m) | $159.30M | $21.13M | (m) | $157.81M | $145.79M | (m) |
| 2017-12-31 | (m) | $150.00M | $32.62M | (m) | $167.04M | $141.44M | (m) |
| 2017-09-30 | (m) | $139.32M | $44.03M | (m) | $146.74M | $149.54M | (m) |
| 2017-06-30 | (m) | $129.71M | $40.14M | (m) | $145.39M | $136.47M | (m) |
| 2017-03-31 | (m) | $125.44M | $34.66M | (m) | $139.85M | $140.08M | (m) |
| 2016-12-31 | (m) | $113.95M | $27.43M | (m) | $148.24M | $135.87M | (m) |
| 2016-09-30 | (m) | $112.86M | $26.95M | (m) | $133.19M | $188.53M | (m) |
| 2016-06-30 | (m) | $106.22M | $23.30M | (m) | $139.62M | $179.91M | (m) |
| 2016-03-31 | (m) | $103.16M | $19.89M | (m) | $134.41M | $185.11M | (m) |
| 2015-12-31 | (m) | $119.72M | $72.50M | (m) | $133.86M | $166.89M | (m) |
| 2015-09-30 | (m) | $111.66M | $65.33M | (m) | $124.70M | $161.56M | (m) |
| 2015-06-30 | (m) | $109.88M | $62.22M | (m) | $129.66M | $149.18M | (m) |
| 2015-03-31 | (m) | $113.48M | $65.73M | (m) | $128.95M | $144.20M | (m) |
| 2014-12-31 | (m) | $115.96M | $66.33M | (m) | $129.29M | $148.15M | (m) |
| 2014-09-30 | (m) | $121.75M | $64.61M | (m) | $123.33M | $162.10M | (m) |
| 2014-06-30 | (m) | $104.62M | $60.41M | (m) | $135.08M | $157.01M | (m) |
| 2014-03-31 | (m) | $101.11M | $56.32M | (m) | $129.83M | $152.17M | (m) |
| 2013-12-31 | (m) | $111.27M | $54.44M | (m) | $140.43M | $143.21M | (m) |
| 2013-09-30 | (m) | $100.88M | $49.83M | (m) | $130.59M | $151.00M | (m) |
| 2013-06-30 | (m) | $99.16M | $38.12M | (m) | $140.57M | $148.72M | (m) |
| 2013-03-31 | (m) | $97.17M | $32.36M | (m) | $135.60M | $156.87M | (m) |
| 2012-12-31 | (m) | $122.51M | $23.72M | (m) | $139.12M | $156.23M | (m) |
| 2012-09-30 | (m) | $125.54M | $19.82M | (m) | $132.87M | $165.33M | (m) |
| 2012-06-30 | (m) | $135.25M | $16.25M | (m) | $136.09M | $159.15M | (m) |
| 2012-03-31 | (m) | $165.84M | $19.45M | (m) | $142.35M | $163.39M | (m) |
| 2011-12-31 | (m) | $131.18M | $26.05M | (m) | $135.64M | $168.44M | (m) |
| 2011-09-30 | (m) | $232.60M | $39.88M | (m) | $130.88M | $174.79M | (m) |
| 2011-06-30 | (m) | $210.35M | $24.33M | (m) | $152.69M | $169.25M | (m) |
| 2011-03-31 | (m) | (m) | $17.94M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $179.87M | $12.42M | (m) | $145.35M | $172.80M | (m) |
| 2010-09-30 | (m) | (m) | $16.52M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $8.49M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $10.10M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $11.81M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B |